Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On April 26, 2024, Lipocine Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners as sa
Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 5.1 Opinion of Dorsey & Whitney LLP 2